---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-076600"
form_type: "8-K"
ticker: "STIM"
cik: "0001227636"
company_name: "Neuronetics, Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:21:19.287302+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Neuronetics gets FDA clearance for NeuroStar as first-line adjunct for adolescent MDD (ages 15-21)

## Summary
- FDA cleared NeuroStar Advanced Therapy as first-line adjunct treatment for major depressive disorder in adolescents aged 15-21.
- Supplemental information posted to Neuronetics IR website on March 25, 2024.
- Expands NeuroStar's indicated population beyond adults to include adolescents with MDD.
- No financial details, revenue guidance, or commercial launch timeline were disclosed.

## SEC filing metadata
- accession: 0001193125-24-076600
- form_type: 8-K
- ticker: STIM
- cik: 0001227636
- company_name: Neuronetics, Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1227636/000119312524076600/0001193125-24-076600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1227636/000119312524076600/d791913d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-076600
- JSON: https://secwatch.observer/filing/0001193125-24-076600.json
- Plain text: https://secwatch.observer/filing/0001193125-24-076600.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.